Treatment of systemic-onset juvenile arthritis with canakinumab
نویسندگان
چکیده
Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the availability of cytokine antagonists targeting interleukin-1 and interleukin-6 have markedly advanced the therapeutic options. In this review, we focus on the current experience with canakinumab, an interleukin-1 monoclonal human antibody for the treatment of systemic-onset juvenile idiopathic arthritis and describe its efficacy and safety. Canakinumab is an important, safe, and valid drug in the treatment of systemic-onset juvenile idiopathic arthritis.
منابع مشابه
Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
BACKGROUND Adult-onset Still's disease (AOSD), a rare autoinflammatory disorder, resembles systemic juvenile idiopathic arthritis (SJIA). The superimposable systemic clinical features of AOSD and SJIA suggest both clinical phenotypes represent the same disease continuum with different ages of onset. To further characterize the similarity between AOSD and SJIA at the molecular level, 2 previousl...
متن کاملCanakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
Introduction Systemic juvenile idiopathic arthritis (SJIA), an interleukin-1b (IL-1b)-mediated autoinflammatory disease, is characterized by recurrent flares of active disease. Treatment with canakinumab (CAN), a selective, human, anti-IL-1b monoclonal antibody allows for successful steroid dose reduction/discontinuation and reduces risk to experience a flare in patients with SJIA [1]. CAN is a...
متن کاملIL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis
Systemic juvenile idiopathic arthritis (sJIA) is the form of childhood arthritis whose treatment is most challenging. The demonstration of the prominent involvement of interleukin (IL)-1 in disease pathogenesis has provided the rationale for the treatment with biologic medications that antagonize this cytokine. The three IL-1 blockers that have been tested so far (anakinra, canakinumab, and ril...
متن کاملGenes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
Introduction Adult-onset Still’s disease (AOSD) is a rare auto-inflammatory disorder resembling a similar pediatric syndrome known as systemic juvenile idiopathic arthritis (SJIA).[1] The superimposable systemic and clinical features in SJIA and AOSD suggest that both clinical phenotypes represent a disease continuum with a pediatric (SJIA) and more adult-onset (AOSD).[2] Analyses of gene expre...
متن کاملEfficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
Results 18 patients aged 4-15 years were included. The median disease duration at treatment onset was 4.7 years (0.48.8). The median dose of prednisone at TCZ onset was 0.63mg/kg/d. Four patients were also on MTX. Fourteen patients had previously failed to respond one or several biologics, including anti-TNF alpha in 10 cases, anakinra in 14 and canakinumab, in 4. All patients but 4 had active ...
متن کامل